BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 30877937)

  • 1. One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI.
    Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Atherosclerosis; 2019 May; 284():102-109. PubMed ID: 30877937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of current smoking on 2-year clinical outcomes between durable-polymer-coated stents and biodegradable-polymer-coated stents in acute myocardial infarction after successful percutaneous coronary intervention: Data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    PLoS One; 2018; 13(10):e0205046. PubMed ID: 30289945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):E40-E55. PubMed ID: 31423723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
    Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Valgimigli M; Windecker S; Pilgrim T
    Int J Cardiol; 2021 Jul; 334():37-41. PubMed ID: 33887341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Clinical Outcomes of Biodegradable-Polymer Drug-Eluting Stents Versus Second-Generation Durable-Polymer Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction.
    Sim HW; Thong EH; Djohan AH; Chen JZ; Ser JS; Loh PH; Lee CH; Chan MY; Low AF; Tay EL; Chan KH; Tan HC; Loh JP
    Cardiovasc Revasc Med; 2022 Feb; 35():98-103. PubMed ID: 33893053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim S; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Int Heart J; 2020 Jul; 61(4):673-684. PubMed ID: 32684595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention.
    Andriyati R; Firman D; Kurniawati Y; Alkatiri AA; Pranata R; Muliawan HS; Rossimarina V; Soerianata S
    Postgrad Med J; 2021 Oct; 97(1152):638-643. PubMed ID: 32796116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Acute Myocardial Infarction Patients Implanted With Biodegradable Polymer Biolimus-Eluting Stents Versus New-Generation Durable Polymer Drug-Eluting Stents: A Retrospective Analysis.
    Choe JC; Cha KS; Jang HY; Choi JH; Kim BW; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Ahn Y; Jeong MH;
    Angiology; 2017 Sep; 68(8):698-706. PubMed ID: 27872316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.
    Song L; Li J; Guan C; Jing Q; Lu S; Yang L; Xu K; Yang Y; Xu B; Han Y;
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):608-616. PubMed ID: 29322619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.
    Räber L; Yamaji K; Kelbæk H; Engstrøm T; Baumbach A; Roffi M; von Birgelen C; Taniwaki M; Moschovitis A; Zaugg S; Ostojic M; Pedrazzini G; Karagiannis-Voules DA; Lüscher TF; Kornowski R; Tüller D; Vukcevic V; Heg D; Windecker S
    Eur Heart J; 2019 Jun; 40(24):1909-1919. PubMed ID: 30851032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population.
    Chandwani P; Verma P; Saxena S; Ramachandran PK; Abhyankar A; Sandhu MS; Parikh N; Bhupali A; Jain S; Prajapati J
    Cardiovasc Hematol Agents Med Chem; 2016; 14(1):39-48. PubMed ID: 26585397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
    Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
    JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.